Sort   by:  
 Page size 
UnknownLenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation.
Not available
S-EPMC10439208 | biostudies-literature
UnknownInfluence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands.
Not available
S-EPMC8591746 | biostudies-literature
UnknownUnbiased mapping of cereblon neosubstrate landscape by high-throughput proteomics.
Not available
S-EPMC12368047 | biostudies-literature
UnknownThalidomide and its metabolite 5-hydroxythalidomide induce teratogenicity via the cereblon neosubstrate PLZF.
Not available
S-EPMC7883055 | biostudies-literature
ProteomicsTargeted MS assay to evaluate Cereblon neosubstrate changes in rabbit embryos following maternal administration of IMiDs
Targeted protein degradation is the selective removal of a protein of interest through hijacking intracellular protein cleanup machinery. This rapidly growing field currently relies heavily on the use of the E3 ligase Cereblon (CRBN) to target proteins for degradation, including the immunomodulatory...
ORGANISM(S): Oryctolagus Cuniculus 
PXD050568 | panorama
ProteomicsMolecular surface mimicry enables CRBN to target G3BP2 for degradation
Molecular glue degraders (MGDs) are small molecule compounds that repurpose the ubiquitin-proteasome system to induce degradation of challenging therapeutic targets. Thalidomide-analogs are clinically effective MGDs that bind cereblon (CRBN), a substrate receptor of the Cullin-4/RING E3 ubiquitin li...
ORGANISM(S): Homo sapiens (Human) 
2026-01-14 | PXD064243 | Pride
Targeted protein degradation Monte rosa therapeutics G3bp2 Crbn Molecular glue 
UnknownMolecular glue CELMoD compounds are regulators of cereblon conformation.
Not available
S-EPMC9714526 | biostudies-literature
UnknownLeveraging Ligand Affinity and Properties: Discovery of Novel Benzamide-Type Cereblon Binders for the Design of PROTACs.
Not available
S-EPMC10641816 | biostudies-literature
UnknownStructural bases of IMiD selectivity that emerges by 5-hydroxythalidomide.
Not available
S-EPMC7490372 | biostudies-literature
ProteomicsMolecular Glue Degraders of HuR to Treat BRAF-Mutant Colorectal Cancer
BRAF gain-of-function mutations, particularly BRAF(V600E), affect roughly 10% of all colorectal cancer (CRC) patients, and portend poor prognosis with limited therapeutic interventions. BRAF inhibitors such as Encorafenib are ineffective due to MAP kinase pathway reactivation driven by BRAF dimeriza...
ORGANISM(S): Homo Sapiens 
2026-04-19 | PXD077365 |
Sort   by:  
 Page size